Figure F-95 is titled “PTSD symptom reduction (any measure) for atypical antipsychotics compared with placebo: Sensitivity analysis including studies with high risk of bias.” The figure displays a forest plot reporting the standardized mean difference in PTSD symptom scores for atypical antipsychotics versus placebo stratified by olanzapine versus placebo and risperidone versus placebo. The plot depicts greater reductions in PTSD symptom scores for patients treated with olanzapine (2 trials, standardized mean difference −0.14, 95% CI −1.80 to 1.53, I2=80.7%) or risperidone (5 trials, standardized mean difference −0.21, 95% CI −0.48 to 0.05, I2=26.6%) than placebo. The overall analysis favored atypical antipsychotics (standardized mean difference −0.21, 95% CI −0.52 to 0.10, I2=43.5%).

Figure F-95PTSD symptom reduction (any measure) for atypical antipsychotics compared with placebo: Sensitivity analysis including studies with high risk of bias

Note: Rothbaum et al., 2008 was rated as high risk of bias.

Timing of outcome assessment: 10 weeks (Butterfield, 2001), 8 weeks (Stein, 2002), 16 weeks (Bartzokis, 2003), 5 weeks (Hamner, 2003), 24 weeks (Krystal, 2011), 8 weeks (Reich, 2004), 16 weeks (Rothbaum, 2008).

From: Appendix F, Meta-Analysis

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.